Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51

Benzinga · 2d ago
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $53 to $51.